Navigation Links
Cancer predisposition from genetic variation shows strong gender bias
Date:9/21/2009

CINCINNATICancer predisposition resulting from the presence of a specific gene variant shows a strong gender bias, researchers at the University of Cincinnati (UC) have demonstrated.

In addition, the research indicates that the risk for development of cancer in individuals harboring the gene variant can be further increased as a result of environmental exposure.

Peter Stambrook, PhD, a professor in the department of molecular genetics, biochemistry and microbiology, and colleagues report their findings this week in Proceedings of the National Academy of Sciences (PNAS). Co-authors include researchers from Wright State University and the Laboratory for Health Protection Research, National Institute of Public Health and the Environment, the Netherlands.

Stambrook says the gene CHEK2 is part of a DNA damage response pathway that can have an impact on whether or not cancers develop. A CHEK2 variant, CHEK2*1100delC, is associated with increased risk of cancer.

"Women who carry this particular gene variant are predisposed to developing breast or ovarian cancer," says Stambrook, "while men have a higher risk of developing prostate cancer."

Stambrook's team has produced a mouse model in which the CHEK2 gene was replaced by the variant and found that the overwhelming majority of mice that developed cancer were femaleabout 80 percent, as opposed to slightly more than 15 percent for males. This contrasts sharply with the incidence of cancer in wild-type mice (those with the normal CHEK2 gene), in which male and female mice developed cancer to about the same extent but at a much lower frequency.

Stambrook says his team will be exploring possible reasons behind the difference, looking at hormonal involvement and possible interactions between the gene variant and estrogen receptors or estrogen itself.

By using a known carcinogen, dimethyl benzanthracene, the researchers also determined that mice that harbor the variant are more susceptible to an environmental challenge than those that don't. The compound was administered orally to female mice.

"When they delivered the compound, the lifespan of the mice was reduced significantlythey developed breast cancer as well as other types of cancers," Stambrook says. "In addition, the mice that harbored this variant were more susceptiblein other words, they developed tumors more quickly than wild-type mice."

Stambrook says that by learning more about the signaling pathway of the CHEK2 gene, researchers can explore ways to "rescue" it and identify potential therapeutic targets.

"It's an interesting gene," says Stambrook, "and there are a lot of interesting directions that this finding will take us."


'/>"/>

Contact: Keith Herrell
keith.herrell@uc.edu
513-558-4559
University of Cincinnati Academic Health Center
Source:Eurekalert

Related medicine news :

1. Head, Neck Cancer Treatment Often Not Completed
2. Researchers Propose Improved Cervical Cancer Screening
3. World Health Organization Launches New Attack on Lung Cancer
4. John Theurer Cancer Center and Leukemia & Lymphoma Society Highlight Upcoming Trends in Hematological Malignancies
5. News from Medialink and P&G: Procter & Gamble Partners with National Breast Cancer Foundation, Inc. to GIVE HOPE to Millions of Women Across the Country
6. Study Published in The Lancet Showed Significant Survival Benefit for Patients Facing Deadly Form of Lung Cancer
7. Surgeon Battling Own Cancer Developed New Treatment
8. New Chemo Regimen May Benefit Ovarian Cancer Patients
9. New Drug May Offer Hope to Some With Lung Cancer
10. Hormone Therapy May Make Lung Cancer More Likely
11. Mens Health Network, The Washington Redskins and GlaxoSmithKline Team Up for Septembers Prostate Cancer Awareness Month
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... ... February 23, 2017 , ... ... for the National Institute for Health and Care Excellence (NICE) framework. ... the National Health Service (NHS) to search, order and purchase medical and healthcare-related ...
(Date:2/23/2017)... ... February 23, 2017 , ... ERT, a ... today announced that Premier Research, a leading clinical development service provider, has selected ... becoming increasingly complex, due in part to an array of circumstances including the ...
(Date:2/23/2017)... ... (PRWEB) ... opportunity for the nation to come together to combine its ... – with its favorite fruit – apples! To celebrate National ... to join the “Apple Madness” bracket tournament – a five-week, ...
(Date:2/23/2017)... , ... February 23, 2017 , ... HealthPostures, the desk ... an expert sit stand solutions representative to the Minneapolis Home and Garden Show which ... the event that is garnering national attention is the Minneapolis Convention Center. , ...
(Date:2/22/2017)... ... February 22, 2017 , ... Our high-octane society demands higher ... sharpest brain. , Power On, a mental performance enhancer from Modus Nutrition, provides ... Each capsule contains Cognizin® Citicoline, a branded form of the brain health nutrient ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... 2017 Nevro Corp. (NYSE: NVRO), a global medical ... treatment of chronic pain, today reported financial results for the ... 2016 Accomplishment & Highlights: Achieved ... increase of 228% as reported, over the prior year ... of 612% over the prior year International ...
(Date:2/23/2017)... , Feb 23, 2017 Research and Markets ... Analysis and Strategies - 2016" report to their offering. ... The latest research ... pricing data and benchmarks in the global Oesophageal Cancer market. ... What are the key drugs marketed for Oesophageal Cancer and ...
(Date:2/23/2017)... , Feb. 23, 2017 Regulus ... the discovery and development of innovative medicines targeting microRNAs, ... year 2016 financial results on Thursday, March 2, 2017 ... a conference call and webcast on March 2, 2017 ... and full year 2016 financial results and provide a ...
Breaking Medicine Technology: